Prosecution Insights
Last updated: April 19, 2026

Examiner: JANOSKO, CHASITY PAIGE

Tech Center 1600 • Art Units: 1613

This examiner grants 15% of resolved cases

Performance Statistics

14.7%
Allow Rate
-45.3% vs TC avg
100
Total Applications
+71.4%
Interview Lift
1225
Avg Prosecution Days
Based on 34 resolved cases, 2023–2026

Rejection Statute Breakdown

1.6%
§101 Eligibility
5.6%
§102 Novelty
48.8%
§103 Obviousness
31.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18009812 METHOD FOR PRODUCING PERSONALIZED COSMETICS Final Rejection BASF SE
17892387 ORAL CARE COMPOSITIONS FOR GUM HEALTH Final Rejection The Procter & Gamble Company
17892353 ORAL CARE COMPOSITIONS FOR GUM HEALTH Final Rejection The Procter & Gamble Company
17926105 FORUMULATION OF MONODISPERSE KINETICALLY FROZEN POLYMER MICELLES VIA EQUILIBRATION-NANOPRECIPITATION Final Rejection Purdue Research Foundation
18250260 OPEN CELL HYDROGEL NETWORKS AND METHODS FOR MAKING AND USING THE SAME Final Rejection University of Florida Research Foundation, Inc.
17907595 SKIN TREATMENT METHOD Non-Final OA Kao Corporation
17637315 COMPOSITION COMPRISING AT LEAST ONE ALKOXYSILANE OF FORMULA (I), AT LEAST ONE ALKOXYSILANE OF FORMULA (II), AT LEAST ONE NONAMINO SILICONE, AND OPTIONALLY PIGMENTS AND/OR DIRECT DYES Non-Final OA L'OREAL
17927550 CERIUM OXIDE NANOPARTICLE, DISPERSION SOLUTION CONTAINING CERIUM OXIDE NANOPARTICLE, OXIDANT, ANTIVIRUS AGENT, AND ANTIBACTERIAL AGENT Non-Final OA Toray Industries, Inc.
17792968 COMPOSITIONS AND METHODS FOR CONTROLLED RELEASE OF TARGET AGENT Final Rejection THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
18042509 ULTRAVIOLET-ABSORPTIVE NANOPARTICLES AND MICROPARTICLES FOR INTRADERMAL USE Non-Final OA THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate
18002041 PIGMENT SUSPENSION AND COSMETIC PRODUCT PREPARED USING THE PIGMENT SUSPENSION Final Rejection Henkel AG & Co. KGaA
18245399 PYRETHROID IN-CAN ADJUVANTED SUSPENSION CONCENTRATES Final Rejection Bayer Aktiengesellschaft
17996538 SOLID DISPERSIONS AND PARTICLES AND METHODS FOR CONTROLLED-RELEASE OF LIPID-SOLUBLE OR DISPESIBLE ACTIVES Final Rejection YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
18264296 COMPOSITIONS COMPRISING A MULTI-TAIL SURFACTANT AND A CATIONIC POLYMER AND USES Non-Final OA RHODIA OPERATIONS
18042424 SILK PARTICLES ENCAPSULATING OXYGEN CARRIERS AS ARTIFICIAL BLOOD SUBSTITUTE Final Rejection University of Florida Research Foundation, Incorporated
18260101 NATURAL OIL-BASED COMPOSITION THAT MIMICS PETROLATUM AND METHOD OF MAKING SAME Final Rejection CARGILL, INCORPORATED
17738686 ADDITIVE MANUFACTURING OF HYDROGEL TUBES FOR BIOMEDICAL APPLICATIONS Non-Final OA Lung Biotechnology PBC
18704112 METHODS OF IMPLANTING ENGINEERED TISSUE CONSTRUCTS Non-Final OA Satellite Biosciences, Inc.
18260297 A SYNERGISTIC PERFUMING COMPOSITION Non-Final OA Firmenich SA
18127373 SUBSTITUTED TOLYL FUNGICIDES Final Rejection FMC CORPORATION
17782734 NEW PROCESS FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS Final Rejection NANEXA AB
18275622 ACTIVE AGENT-RELEASING HYALURONIC ACID VEHICLE Non-Final OA Ariel Scientific Innovations Ltd.
17602356 PROCESS FOR CONTINUOUS PRODUCTION OF AN ACTIVE INGREDIENT GRANULATE Final Rejection ADD Advanced Drug Delivery Technologies Ltd.
17824237 SOLID DISPERSION OF PAN-RAF KINASE INHIBITOR Non-Final OA DAY ONE BIOPHARMACEUTICALS, INC.
18264301 MULTIPHASIC LIQUID COMPOSITIONS FOR IMPROVED DEPOSITION OF ACTIVE INGREDIENTS Non-Final OA SPECIALITY OPERATIONS FRANCE
17777415 NEW COMPOSITIONS OF SUCRALFATE IN ALGINATE AND THEIR USE IN THERAPY Final Rejection NYUMA PHARMA SRL
18248044 GELMA POLYMER COMPOSITIONS AND USES THEREOF Non-Final OA GELMEDIX, INC.
17631651 HARD CAPSULE FORMULATION SEALED WITH BAND SEAL CONTAINING TAGS Non-Final OA QUALICAPS CO., LTD.
18006509 OPHTHALMIC LIQUID COMPOSITION Final Rejection PANGEN BIOTECH INC.
18016696 Agrochemical mixtures of diamides, plant health additives and insecticide Final Rejection RAJDHANI PETROCHEMICALS PRIVATE LIMITED

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month